VOLUNTARY ANNOUNCEMENT - HIGHLY SELECTIVE KAT6 INHIBITOR (SYH2059 TABLETS) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.

Hong Kong Exchanges and Clearing Limited and The Stock Excha nge of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoe ver for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this ann ouncement. CSPC PHARMACEUTICAL GROUP LIMITED (Incorporated in Hong Kong with limited liability) (Stock Code: 1093) ʮ ̡ VOLUNTARY ANNOUNCEMENT HIGHLY SELECTIVE KAT6 INHIBITOR (SYH2059 TABLETS) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S. The Board of Directors (the ‘‘Board ’’) of CSPC Pharmaceutical Group Limited (the ‘‘Company ’’, together with its subsidiaries, the ‘‘Group ’’) is pleased to announce that the SYH2095 tablets (the ‘‘Product ’’), a Class 1 chemical new drug co-developed by the Group and Ha ngzhou Innogate Pharma Co., Ltd., has obtained approval from the U.S. Food and Drug A dministration (FDA) to conduct clinical trials in the U.S. The Product is a novel, highly selective lysine acetyltrans ferase 6 ( ‘‘KAT6 ’’) inhibitor and belongs to a class of epigenetic anticancer drugs. The Product exerts it s anti-tumor effects by inhibiting the acetylation of histone lysine, blocking open chromatin, an d thereby regulating the cell cycle, estrogen receptor expression, and cellular senescence pathways. It is intended for the treatment of advanced malignant tumors. Preclinical studies showed that the Prod uct demonstrated potent and selective inhibition of KAT6, significantly suppressed tumor growth , and exhibited favourable pharmacokinetic properties and safety profile. Currently, no drug with the same target has been approved for marketing domestically or internationally, and the Product has significant clinical development value. By order of the Board CSPC Pharmaceutical Group Limited CAI Dong Chen Chairman Hong Kong, 24 April 2026 As at the date of this announcement, the Board comprises Mr. C AI Dong Chen, Dr. CAI Lei, Mr. WEI Qingjie, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. WANG Huaiy u, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin, Mr. CHEN Weiping, Mr. QU Zhiyong and Mr. ZHANG Yiw ei as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Dir ectors.

The release as fetched from its publisher. irasia.com ↗